XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Equity
 3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Equity Equity
The following summarizes the changes in equity for the three months ended March 31, 2023 and 2022 (dollars in thousands):
Common
stock		Additional
paid-in
capital		Accumulated
earnings
less
dividends		Accumulated
other
comprehensive
income (loss)		Total stockholder's equityNoncontrolling interestsTotal
equity
Balance at December 31, 2022$1,400 $10,765,431 $485,221 $1,424 $11,253,476 $77 $11,253,553 
Net income attributable to common stockholders— — 146,902 — 146,902 — 146,902 
Loss on cash flow hedges, net— — — (340)(340)— (340)
Cash flow hedge losses reclassified to earnings— — — 354 354 — 354 
Change in redemption value of redeemable noncontrolling interest— — (286)— (286)— (286)
Dividends declared to common stockholders ($1.65 per share)
— — (230,958)— (230,958)— (230,958)
Issuance of common stock, net of withholdings1 (11,554)1,590 — (9,963)— (9,963)
Repurchase of common stock, including repurchase costs— (539)(590)— (1,129)— (1,129)
Amortization of deferred compensation— 11,123 — — 11,123 — 11,123 
Balance at March 31, 2023$1,401 $10,764,461 $401,879 $1,438 $11,169,179 $77 $11,169,256 

Common
stock		Additional
paid-in
capital		Accumulated
earnings
less
dividends		Accumulated
other
comprehensive
income (loss)		Total stockholder's equityNoncontrolling interestsTotal
equity
Balance at December 31, 2021$1,398 $10,716,414 $240,821 $(26,106)$10,932,527 $566 $10,933,093 
Net income attributable to common stockholders— — 262,044 — 262,044 — 262,044 
Gain on cash flow hedges, net— — — 10,155 10,155 — 10,155 
Cash flow hedge losses reclassified to earnings— — — 1,013 1,013 — 1,013 
Change in redemption value of redeemable noncontrolling interest— — (43)— (43)— (43)
Noncontrolling interest distribution and income allocation— — — — — (10)(10)
Dividends declared to common stockholders ($1.59 per share)
— — (222,373)— (222,373)— (222,373)
Issuance of common stock, net of withholdings1 (14,263)(1,501)— (15,763)— (15,763)
Amortization of deferred compensation— 9,176 — — 9,176 — 9,176 
Balance at March 31, 2022$1,399 $10,711,327 $278,948 $(14,938)$10,976,736 $556 $10,977,292 

As of March 31, 2023 and December 31, 2022, the Company's charter had authorized for issuance a total of 280,000,000 shares of common stock and 50,000,000 shares of preferred stock.
During the three months ended March 31, 2023, the Company:

i.issued 1,932 shares of common stock in connection with stock options exercised;
ii.issued 847 shares of common stock through the Company's dividend reinvestment plan;
iii.issued 151,053 shares of common stock in connection with restricted stock grants and the conversion of performance awards to shares of common stock;
iv.withheld 60,693 shares of common stock to satisfy employees' tax withholding and other liabilities;
v.canceled 147 shares of restricted common stock upon forfeiture; and
vi.repurchased 7,000 common shares through the 2020 Stock Repurchase Program.

Deferred compensation granted under the Company's Second Amended and Restated 2009 Equity Incentive Plan (the "2009 Plan") for the three months ended March 31, 2023 does not impact the Company's Condensed Consolidated Financial Statements until recognized as compensation cost.

In July 2020, the Company’s Board of Directors approved a stock repurchase program under which the Company may acquire shares of its common stock in open market or negotiated transactions up to an aggregate purchase price of $500,000,000 (the "2020 Stock Repurchase Program"). Purchases of common stock under the 2020 Stock Repurchase Program may be exercised at the Company’s discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements and other corporate liquidity requirements and priorities. The 2020 Stock Repurchase Program does not have an expiration date and may be suspended or terminated at any time without prior notice. During the three months ended March 31, 2023, the Company repurchased 7,000 shares of common stock at an average price of $161.29 per share. As of March 31, 2023, the Company had $315,019,000 remaining authorized for purchase under this program.

In May 2019, the Company commenced a fifth continuous equity program ("CEP V") under which the Company may sell (and/or enter into forward sale agreements for the sale of) up to $1,000,000,000 of its common stock from time to time. Actual sales will depend on a variety of factors to be determined by the Company, including market conditions, the trading price of the Company's common stock and the Company's determinations of the appropriate funding sources. The Company engaged sales agents for CEP V who receive compensation of up to 1.5% of the gross sales price for shares sold. The Company expects that, if entered into, it will physically settle each forward sale agreement on one or more dates specified by the Company on or prior to the maturity date of that particular forward sale agreement, in which case the Company will receive aggregate net cash proceeds at settlement equal to the number of shares underlying the particular forward agreement multiplied by the forward sale price. However, the Company may also elect to cash settle or net share settle a forward sale agreement. In connection with each forward sale agreement, the Company will pay the forward seller, in the form of a reduced initial forward sale price, a commission of up to 1.5% of the sales prices of all borrowed shares of common stock sold. During the three months ended March 31, 2023, the Company had no sales under this program. As of March 31, 2023, the Company had $705,961,000 remaining authorized for issuance under CEP V.

In addition to CEP V, during April 2022, the Company completed an underwritten public offering of 2,000,000 shares of its common stock for an initial net forward sales price of $247.30 per share, after offering fees and discounts, offered in connection with forward contracts entered into with certain financial institutions acting as forward purchasers (the "Equity Forward") (see Note 12, "Subsequent Events" for a discussion of the settlement of the Equity Forward in April 2023).